Speaker Profile

CEO, Novome Biotechnologies

Blake Wise is Chief Executive Officer at Novome Biotechnologies, a biotechnology company focused on developing engineered cellular therapies for the gut to treat chronic diseases. Prior to Novome, Mr. Wise served as Chief Executive Officer of Achaogen where he oversaw the development and FDA approval of ZEMDRI (plazomicin) for adults with complicated urinary tract infections. Prior to joining Achaogen, Mr. Wise spent 13 years at Genentech in multiple leadership positions of increasing responsibility, including Vice President in Genentech’s BioOncology business unit. Prior to joining Genentech, Mr. Wise worked in consumer marketing, e-commerce and online marketing in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.

Emerging Therapeutics Showcase:
Novome Biotechnologies

Novome Biotechnologies is a clinical stage biotechnology company developing engineered cellular therapies for the gut to treat chronic diseases.

Engineering Living Medicines for Chronic Diseases
In this talk, we discuss Novome’s novel foundational technology for controllably colonizing the gut with therapeutically engineered cells, our broad pipeline, and clinical results from a Phase 1 healthy volunteer study of our lead program, NOV-001.

 Session Abstract – PMWC 2022 Silicon Valley

Track 7 - June 28 9.30 A.M.-9.45 A.M.,Track 7 - June 29 3.30 P.M.-3.45 P.M.,Track 7 - June 30 1.00 P.M.-1.15 P.M.

The PMWC 2022 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.

- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy


Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by SEP. 28TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required